NantKwest rises 21% on ImmunityBio merger deal

Dec. 21, 2020 6:24 AM ETImmunityBio, Inc. (IBRX)By: Mamta Mayani, SA News Editor
  • NantKwest (NK), up 21% premarket, and privately-held ImmunityBio have entered into an agreement to merge in a stock-for-stock transaction. The combination will create an immunotherapy and cell therapy company focused on oncology and infectious disease.
  • Together, ImmunityBio and NantKwest will have a broad, clinical-stage

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.